These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28501538)

  • 1. Biopsy Specimens From Allograft Liver Contain Histologic Features of Hepatitis C Virus Infection After Virus Eradication.
    Whitcomb E; Choi WT; Jerome KR; Cook L; Landis C; Ahn J; Te HS; Esfeh J; Hanouneh IA; Rayhill SC; Gibson W; Plesec T; Koo J; Wang HL; Hart J; Pai RK; Westerhoff M
    Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1279-1285. PubMed ID: 28501538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
    Dhanasekaran R; Sanchez W; Mounajjed T; Wiesner RH; Watt KD; Charlton MR
    Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.
    Campos-Varela I; Castells L; Esteban JI; Bes M; Rodríguez-Frías F; Sapisochin G; Allende H; Charco R; Esteban R
    Transplantation; 2012 Feb; 93(4):450-3. PubMed ID: 22262129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report.
    Yamamoto T; Tanaka S; Uenishi T; Kanazawa A; Kubo S; Hirohashi K
    Osaka City Med J; 2014 Dec; 60(2):95-100. PubMed ID: 25803885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
    Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
    Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study.
    Guerrero RB; Batts KP; Burgart LJ; Barrett SL; Germer JJ; Poterucha JJ; Wiesner RH; Charlton MR; Persing DH
    Mod Pathol; 2000 Mar; 13(3):229-37. PubMed ID: 10757333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.
    Wang Y; Rao H; Chi X; Li B; Liu H; Wu L; Zhang H; Liu S; Zhou G; Li N; Niu J; Wei L; Zhao J
    EBioMedicine; 2019 Aug; 46():227-235. PubMed ID: 31345785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.
    Maylin S; Martinot-Peignoux M; Moucari R; Boyer N; Ripault MP; Cazals-Hatem D; Giuily N; Castelnau C; Cardoso AC; Asselah T; Féray C; Nicolas-Chanoine MH; Bedossa P; Marcellin P
    Gastroenterology; 2008 Sep; 135(3):821-9. PubMed ID: 18593587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response.
    Liu A; Angirekula M; Elhawary A; Mara K; Kulai T; Leise M; Watt KD
    Clin Transplant; 2023 Oct; 37(10):e15050. PubMed ID: 37329298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spectrum of histopathological findings after SVR to DAA for recurrent HCV infection in liver transplant recipients.
    Sanghi V; Romero-Marrero C; Flocco G; Graham RP; Abduljawad B; Niyazi F; Asfari MM; Hashimoto K; Eghtesad B; Menon KVN; Aucejo FN; Lopez R; Yerian LM; Allende DS
    Virchows Arch; 2022 Feb; 480(2):335-347. PubMed ID: 34498114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
    Beig J; Orr D; Harrison B; Gane E
    Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
    Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
    Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
    J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin.
    McHutchison JG; Poynard T; Esteban-Mur R; Davis GL; Goodman ZD; Harvey J; Ling MH; Garaud JJ; Albrecht JK; Patel K; Dienstag JL; Morgan T;
    Hepatology; 2002 Mar; 35(3):688-93. PubMed ID: 11870385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
    Morishima C; Morgan TR; Everhart JE; Wright EC; Shiffman ML; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Gretch DR;
    Hepatology; 2006 Aug; 44(2):360-7. PubMed ID: 16871570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplantation of liver from hepatitis C-infected donors to hepatitis C RNA-negative recipients: Histological and virologic outcome.
    Nair SP; Marella HK; Maliakkal B; Snyder H; Handley C; Kothadia JP; Ali B; Satapathy SK; Molnar MZ; Clark I; Jain R; Helmick R; Eymard C; Eason JD
    Clin Transplant; 2021 May; 35(5):e14281. PubMed ID: 33690929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes.
    Molnar MZ; Azhar A; Tsujita M; Talwar M; Balaraman V; Bhalla A; Podila PSB; Kothadia J; Agbim UA; Maliakkal B; Satapathy SK; Kovesdy CP; Nair S; Eason JD
    Am J Kidney Dis; 2021 May; 77(5):739-747.e1. PubMed ID: 33333148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents.
    Del Bello A; Abravanel F; Alric L; Lavayssiere L; Lhomme S; Bellière J; Izopet J; Kamar N
    Transpl Infect Dis; 2019 Aug; 21(4):e13093. PubMed ID: 30972874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.